Clinical Trial Update: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of PDS0101 and pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• PDS0101
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: PDS Biotechnology Corp. | Conditions: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2 | Status: COMPLETED